WJ-PURE is under clinical development by Vitti Labs and currently in Phase I for Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WJ-PURE’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WJ-PURE overview

WJ-PURE is under development for the treatment of Alzheimer's disease, chronic obstructive pulmonary disease (COPD), osteoarthritis, COVID induced pulmonary fibrosis, COVID-19 associated acute respiratory distress syndrome and Duchenne muscular dystrophy. The therapeutic candidate comprises umbilical cord derived mesenchymal stem cells.

Vitti Labs overview

Vitti Labs is focused on life science research, development and manufacturing. Vitti Labs is headquartered in Liberty, Missouri, the US.

For a complete picture of WJ-PURE’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.